ArticleDrug delivery2018

Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.

Xiaolong Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.